epstein–barr virus positive diffuse large b-cell lymphoma, not otherwise specified epstein–barr virus positive diffuse large b-cell lymphoma, not otherwise specified epstein–barr virus positive diffuse large b-cell lymphoma, not otherwise specified (also termed: ebv positive diffuse large b cell lymphoma, nos; ebv+ dlbcl, nos; or ebv+ dlbcl) was initially termed in the who 2008 classification as epstein–barr virus-positive dlbcl of the elderly because it was a specific type of large b-cell lymphoma that appeared to be limited to elderly (e.g. >50 years old) individuals.: 369–370 since this 2008 who classification, however, the disorder has been diagnosed in much younger adults and children. accordingly, the who classification of 2016 renamed this order as ebv+ dlbcl, nos. the disease is also classified as one of numerous related and interrelated epstein-barr virus-associated lymphoproliferative diseases. ebv+ dlbcl, nos is usually cd20 positive, and has clonal immunoglobulin gene rearrangement.: 380 biology this type of lymphoma is not associated with immunodeficiency.: 369 although reported almost exclusively in asians, it is not confined to that population.: 369 the disease usually has an extranodal presentation, with or without lymph node involvement.: 369 morphologically, areas of necrosis are often seen: 370 as well as reed–sternberg-like cells.: 370 there are two subtypes: one with monotonous large cells, the other with numerous cell sizes as well as reactive cells, but different clinical behavior is not appreciated between these subtypes.: 370 morphological differential diagnosis is hodgkin lymphoma.: 370 median survival 2 years, 25% 5-year survival.: 369